SM
TBPH icon

SG3 Management’s Theravance Biopharma TBPH Stock Holding History

SG3 Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24,800
Closed -$237K – 808
2022
Q1 		$237K Buy
+24,800
New +$243K 0.01% 735
2021
Q2 		– Sell
-13,000
Closed -$265K – 1328
2021
Q1 		$265K Buy
+13,000
New +$247K 0.01% 911

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG3 Management's TBPH Position: Q2 2022 in Review

SG3 Management sold out of Theravance Biopharma (TBPH) in Q2 2022, closing a stake of 24,800 shares — an estimated $237K sold.

SG3 Management first reported a position in TBPH in Q1 2021 and held it in 2 quarters. The position peaked at $265K in Q1 2021. 113 funds tracked by Wall St. Rank hold TBPH as of Q2 2022.

  • SG3 Management reported no remaining Theravance Biopharma position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 24,800 Theravance Biopharma shares in Q2 2022, an estimated $237K.
  • SG3 Management first reported a position in Theravance Biopharma in Q1 2021 and held it in 2 quarters.
  • SG3 Management's Theravance Biopharma position peaked at $265K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.